Page content

Page breadcrumb

7.3 Contraception

First line drugs Second line drugs Specialist drugs Secondary care drugs

Traffic light status (TLS) explained: 

  • Green: Routine prescribing within licensed indication
  • Amber 1: specialist recommendation followed by GP initiation and continuation
  • Amber 2: specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation
  • Amber 3: specialist initiation and stabilisation followed by GP continuation
  • Amber SCG: specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline
  • Red: Hospital or specialist prescribing only
  • Double Red: These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.

 

 

 

Contraception

Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using contraceptives can be found on the SPC website for each medicine.

The information is either embedded in the SPC of the medicine or can be accessed by clicking the "Risk Materials" tab on the SPC page of the medicine.

 

Medicines: summary of recommendations

Our recommended Formulary brands can be found by clicking on summary of recommendations and covers the following:

7.3.1 Contraception, combined

7.3.2 Contraception, devices (there are no products on the formulary)

7.3.3 Contraception, emergency

7.3.4 Contraception, oral progestogen-only

7.3.5 Contraception, parenteral progestogen-only - see notes below

7.3.6 Contraception, spermicidal (there are no products on the formulary)

 

Notes (for 7.3.5):

  • Latest advice is that the interval between injections does not need to be altered when an enzyme-inducing drug is also prescribed (even rifampicin). 
  • Sayana Press should only be prescribed for compliant patients who have received the relevant training and understand the importance of strictly adhering to the administration regimen 
  • A woman should be proved to be not pregnant before treatment is commenced and the manufacturer’s leaflet given (with time to read it and any questions answered) before she decides on injectable contraception.   

 

 

 

 

Appendices

Return to Chapter: 7. Obstetrics, Gynaecology and Urinary-tract Disorders

Last updated by: Sheila Wood on 13-05-2019 13:46